Primary brain tumours in adults

MJ van den Bent, M Geurts, PJ French, M Smits… - The Lancet, 2023 - thelancet.com
The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of
rarer CNS tumour types exists. The classification of these tumours is increasingly based on …

Vorasidenib in IDH1-or IDH2-mutant low-grade glioma

IK Mellinghoff, MJ Van Den Bent… - … England Journal of …, 2023 - Mass Medical Soc
Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …

Molecular profiling and targeted therapies in gliomas

Y Felistia, PY Wen - Current Neurology and Neuroscience Reports, 2023 - Springer
Abstract Purpose of Review Molecular profiling enables the evaluation of genetic alterations
for the diagnosis and classification of gliomas and the selection of appropriate therapies …

Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma

A Bhatia, R Moreno, AS Reiner, S Nandakumar… - Clinical Cancer …, 2024 - AACR
Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain
tumors characterized by a slow-growing phase over several years followed by a rapid …

Immunotherapy approaches in isocitrate-dehydrogenase-mutant low-grade glioma

M Gallus, D Kwok, S Lakshmanachetty, A Yamamichi… - Cancers, 2023 - mdpi.com
Simple Summary IDH-mutant low-grade gliomas (LGG) are slow-growing glial cell-derived
tumors of the central nervous system (CNS) that predominantly manifest in young adults and …

Molecular profiling in neuro-oncology: where we are, where we're heading, and how we ensure everyone can come along

AB Porter, PY Wen, MYC Polley - American Society of Clinical …, 2023 - ascopubs.org
Advances in molecular profiling have led to improved understanding of glioma
heterogeneity. Results have been used to inform diagnostic classification and targeted …

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma

QX Wang, PY Zhang, QQ Li, ZJ Tong, JZ Wu… - European Journal of …, 2023 - Elsevier
Glioma is one of the most common types of brain tumors, and its high recurrence and
mortality rates threaten human health. In 2008, the frequent isocitrate dehydrogenase 1 …

Electrochemical Nanoreactor Provides a Comprehensive View of Isocitrate Dehydrogenase Cancer‐drug Kinetics

RA Herold, CJ Schofield, FA Armstrong - Angewandte Chemie, 2023 - Wiley Online Library
The ability to control enzyme cascades entrapped in a nanoporous electrode material (the
“Electrochemical Leaf”, e‐Leaf) has been exploited to gain detailed kinetic insight into the …

[HTML][HTML] 2-hydroxyglutarate rides the cancer-immunity cycle

IP Foskolou, L Bunse, J Van den Bossche - Current opinion in …, 2023 - Elsevier
Highlights•Cancer cell-derived D-and L-2HG regulate antitumor immunity.•Both 2HG
enantiomers physiologically accumulate in immune cells.•D-2HG and L-2HG should not be …

Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity

M Cai, J Zhao, Q Ding, J Wei - Heliyon, 2024 - cell.com
Abstract" Oncometabolite" 2-hydroxyglutarate (2-HG) is an aberrant metabolite found in
tumor cells, exerting a pivotal influence on tumor progression. Recent studies have unveiled …